Faheem Hasnain, EVP, Oncology/Rheumatology SBU at BIOGEN IDEC INC. (BIIB), sold 6,425 shares at $63.71 ($414K) on 2008-04-08, disclosed to the SEC on 2008-04-10.
Scheduled sale ($414k) by EVP, Oncology/Rheumatology SBU under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $63.71 | 100 | $6K | 1.5% |
| 2 | $63.79 | 200 | $13K | 3.1% |
| 3 | $63.89 | 200 | $13K | 3.1% |
| 4 | $63.93 | 100 | $6K | 1.5% |
| 5 | $64.18 | 300 | $19K | 4.6% |
| 6 | $64.32 | 500 |
| $32K |
| 7.8% |
| 7 | $64.38 | 400 | $26K | 6.2% |
| 8 | $64.39 | 2 | $129 | 0.0% |
| 9 | $64.40 | 200 | $13K | 3.1% |
| 10 | $64.42 | 998 | $64K | 15.5% |
| 11 | $64.44 | 800 | $52K | 12.4% |
| 12 | $64.48 | 25 | $2K | 0.4% |
| 13 | $64.51 | 300 | $19K | 4.7% |
| 14 | $64.54 | 100 | $6K | 1.6% |
| 15 | $64.58 | 100 | $6K | 1.6% |
| 16 | $64.61 | 100 | $6K | 1.6% |
| 17 | $64.63 | 300 | $19K | 4.7% |
| 18 | $64.64 | 100 | $6K | 1.6% |
| 19 | $64.67 | 100 | $6K | 1.6% |
| 20 | $64.72 | 300 | $19K | 4.7% |
| 21 | $64.79 | 400 | $26K | 6.3% |
| 22 | $64.82 | 400 | $26K | 6.3% |
| 23 | $64.92 | 100 | $6K | 1.6% |
| 24 | $64.93 | 200 | $13K | 3.1% |
| 25 | $64.94 | 100 | $6K | 1.6% |
| Total | $64.47 avg | 6,425 | $414K | 100% |
| Filing → |
| GOSS | BUY | 2024-06-24 | $498K | — | Filing → |
| GOSS | SELL | 2024-03-28 | $27K | — | Filing → |
| MRTX | BUY | 2023-08-14 | $600K | — | Filing → |